Macrophage Membrane-Cloaked ROS-Responsive Albumin Nanoplatforms for Targeted Delivery of Curcumin to Alleviate Acute Liver Injury
Molecular Pharmaceutics · 03.02.2025 · 22 (2) · 771-786
DOI: 10.1021/acs.molpharmaceut.4c00808 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 09.01.2025. Verfasst von Dandan Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University,…. Hauptthemen laut MEDLINE: Curcumin, Reactive Oxygen Species, Macrophages, Nanoparticles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China, Technical Innovation Research and Development Project of Chengdu.
Abstract (Originalsprache)
Developing low-toxicity, high-efficacy, and fast-acting strategies to manage acute liver injury (ALI) is critical due to its rapid progression and potential for severe outcomes. Curcumin (CUR) has shown promise in ALI therapy due to its ability to modulate the inflammatory microenvironment by scavenging reactive oxygen species (ROS). Nevertheless, CUR is highly hydrophobic limiting its bioavailability and effective in vivo transport, which hinders its further application. In this study, we developed an inflammatory microenvironment-targeted drug delivery system by covalently coupling human serum albumin (HSA) with ROS-sensitive thioketal linkers and loading it with CUR to form nanoparticles (HSA-TK/CUR). These nanoparticles were then coated with a macrophage membrane (CM@HSA-TK/CUR), resulting in negatively charged spherical particles (≈ -23.26 mV) with an average particle size of around 165 nm. ROS responsiveness was confirmed through drug release assays and enhanced ROS depletion was further demonstrated by Diacetyldichlorofluorescein (DCFH-DA) ROS detection experiments. CM@HSA-TK/CUR treatment resulted in a 94.7% reduction in ROS levels in inflammatory cells. In addition, cellular uptake and in vivo distribution experiments demonstrated that camouflaging HSA-TK/CUR with macrophage membranes significantly enhanced its targeting of the inflammatory microenvironment. The findings revealed that CM@HSA-TK/CUR rapidly accumulated in the injured liver within 6 h, inhibited the production of pro-inflammatory factors (IL-1β, IL-6, and TNF-α), shifted macrophage polarization from M1 to M2 in vivo, and protected hepatocytes from oxidative stress-associated cell death, significantly attenuating the inflammatory response in ALI mice. In conclusion, CM@HSA-TK/CUR has excellent potential in treating mice with ALI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs, School of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China.
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- Technical Innovation Research and Development Project of Chengdu
Zitieren
APA
Hu, D., Huang, Z., Li, W., Shan, L., Wu, M. Y., Feng, S., & Wan, Y. (2025). Macrophage Membrane-Cloaked ROS-Responsive Albumin Nanoplatforms for Targeted Delivery of Curcumin to Alleviate Acute Liver Injury. Molecular Pharmaceutics, 22(2), 771-786. https://doi.org/10.1021/acs.molpharmaceut.4c00808
Vancouver
Hu D, Huang Z, Li W, Shan L, Wu MY, Feng S, et al. Macrophage Membrane-Cloaked ROS-Responsive Albumin Nanoplatforms for Targeted Delivery of Curcumin to Alleviate Acute Liver Injury. Molecular Pharmaceutics. 2025;22(2):771-786. doi:10.1021/acs.molpharmaceut.4c00808
BibTeX
@article{Hu2025,
author = {Hu, Dandan and Huang, Zhenqiu and Li, Wenlong and Shan, Lianhai and Wu, Ming-Yu and Feng, Shun and Wan, Yu},
title = {Macrophage Membrane-Cloaked ROS-Responsive Albumin Nanoplatforms for Targeted Delivery of Curcumin to Alleviate Acute Liver Injury},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {2},
pages = {771--786},
doi = {10.1021/acs.molpharmaceut.4c00808}
}
EUVIMED